PPA
CHRS icon

Parametric Portfolio Associates’s Coherus Oncology CHRS Stock Holding History

Parametric Portfolio Associates’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.5M Sell
116,069
-68,435
-37% -$870K ﹤0.01% 2571
2021
Q4 		$2.94M Sell
184,504
-15,667
-8% -$274K ﹤0.01% 2207
2021
Q3 		$3.22M Buy
200,171
+53,568
+37% +$785K ﹤0.01% 2137
2021
Q2 		$2.03M Buy
146,603
+61,246
+72% +$867K ﹤0.01% 2428
2021
Q1 		$1.25M Sell
85,357
-24,502
-22% -$416K ﹤0.01% 3055
2020
Q4 		$1.91M Sell
109,859
-14,058
-11% -$250K ﹤0.01% 2682
2020
Q3 		$2.27M Buy
123,917
+49,954
+68% +$929K ﹤0.01% 2431
2020
Q2 		$1.32M Sell
73,963
-92,968
-56% -$1.57M ﹤0.01% 2762
2020
Q1 		$2.71M Buy
166,931
+95,588
+134% +$1.77M ﹤0.01% 2182
2019
Q4 		$1.28M Sell
71,343
-1,828
-2% -$33.7K ﹤0.01% 2927
2019
Q3 		$1.48M Sell
73,171
-21,517
-23% -$430K ﹤0.01% 2811
2019
Q2 		$2.09M Buy
+94,688
New +$1.64M ﹤0.01% 2646
2018
Q3 		– Sell
-10,344
Closed -$145K – 3944
2018
Q2 		$145K Sell
10,344
-11,389
-52% -$163K ﹤0.01% 3758
2018
Q1 		$240K Buy
21,733
+1,783
+9% +$19.5K ﹤0.01% 3688
2017
Q4 		$176K Buy
+19,950
New +$214K ﹤0.01% 3773

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Parametric Portfolio Associates's CHRS Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Coherus Oncology (CHRS) stake by 37% in Q1 2022, selling an estimated $870K and leaving 116,069 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Parametric Portfolio Associates first reported a position in CHRS in Q4 2017 and has held it in 15 quarters since. The position peaked at $3.22M in Q3 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Parametric Portfolio Associates held 116,069 shares of Coherus Oncology worth $1.5M as of Q1 2022.
  • Parametric Portfolio Associates sold 68,435 Coherus Oncology shares in Q1 2022, an estimated $870K.
  • Coherus Oncology made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2571 holding.
  • Parametric Portfolio Associates first reported a position in Coherus Oncology in Q4 2017 and has held it in 15 quarters since.
  • Parametric Portfolio Associates's Coherus Oncology position peaked at $3.22M in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.